Prantesh Jain

Dr. Prantesh Jain

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Therapeutic Advances in Respiratory Disease
Verified
Journal Article
Open access
PJPrantesh Jain
Prantesh Jain
CJChhavi Jain
Chhavi Jain
VVVamsidhar Velcheti
Vamsidhar Velcheti
Immune checkpoint inhibitors, mainly drugs targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA4) pathways, represent a remarkable advance in lung cancer treatment. Immune checkpoint inhibitors targeting PD-1 and PD-L1 are approved for the treatment of patients with non-small-cell lung cancer, with impressive clinical activity and durable responses in some patients. This review will summarize the mechanism of action of these drugs, the clinical development of these agents and the current role of these agents in the management of patients with lung cancer. In addition, the review will discuss the role of predictive biomarkers for optimal patient selection for immunotherapy and management of autoimmune side effects of these agents.

1 September 2019 in Lung Cancer
Verified
Journal Article
Closed access
MKMohammadhadi Khorrami
Mohammadhadi Khorrami
PJPrantesh Jain
Prantesh Jain
KBKaustav Bera
Kaustav Bera
MAMehdi Alilou
Mehdi Alilou
RTRajat Thawani
Rajat Thawani
Anant MadabhushiAnant Madabhushi
Anant Madabhushi

27 August 2021 in ESMO Open
Verified
Journal Article
Open access
PJPrantesh Jain
Prantesh Jain
JBJ. Gutierrez Bugarin
J. Gutierrez Bugarin
Avirup GuhaAvirup Guha
Avirup Guha
CJC. Jain
C. Jain
NPN. Patil
N. Patil
ADA. Dowlati
A. Dowlati
Immune checkpoint inhibitors (ICIs) can cause life-threatening cardiovascular adverse events (CVAEs) that may not be attributed to therapy. The outcomes of clinical trials may underestimate treatment-related adverse events due to restrictive eligibility, limited sample size, and failure to anticipate selected toxicities. We evaluated the incidence and clinical determinants of CVAEs in real-world population on ICI therapy. Among 2 687 301 patients diagnosed with cancer from 2011 to 2018, 16 574 received ICIs for any cancer. Patients in the ICI and non-ICI cohorts were matched in a 1 : 1 ratio according to age, sex, National Cancer Institute comorbidity score, and primary cancer. The non-ICI cohort was stratified into patients who received chemotherapy (N = 2875) or targeted agents (N = 4611). All CVAEs, non-cardiac immune-related adverse events occurring after treatment initiation, baseline comorbidities, and treatment details were identified and analyzed using diagnosis and billing codes. Median age was 61 and 65 years in the ICI and non-ICI cohorts, respectively (P < 0.001). ICI patients were predominantly male (P < 0.001). Lung cancer (43.1%), melanoma (30.4%), and renal cell carcinoma (9.9%) were the most common cancer types. CVAE diagnoses in our dataset by incidence proportion (ICI cohort) were stroke (4.6%), heart failure (3.5%), atrial fibrillation (2.1%), conduction disorders (1.5%), myocardial infarction (0.9%), myocarditis (0.05%), vasculitis (0.05%), and pericarditis (0.2%). Anti-cytotoxic T-lymphocyte-associated protein 4 increased the risk of heart failure [versus anti-programmed cell death protein 1; hazard ratio (HR), 1.9; 95% confidence interval (CI) 1.27-2.84] and stroke (HR, 1.7; 95% CI 1.3-2.22). Pneumonitis was associated with heart failure (HR, 2.61; 95% CI 1.23-5.52) and encephalitis with conduction disorders (HR, 4.35; 95% CI 1.6-11.87) in patients on ICIs. Advanced age, primary cancer, nephritis, and anti-cytotoxic T-lymphocyte-associated protein 4 therapy were commonly associated with CVAEs in the adjusted Cox proportional hazards model. Our findings underscore the importance of risk stratification and cardiovascular monitoring for patients on ICI therapy.

1 May 2018 in Clinical Lung Cancer
Verified
Journal Article
Closed access
MKMonica Khunger
Monica Khunger
PJPrantesh Jain
Prantesh Jain
SRSagar Rakshit
Sagar Rakshit
VPVinay Pasupuleti
Vinay Pasupuleti
Adrian V. HernandezAdrian V. Hernandez
Adrian V. Hernandez
VVVamsidhar Velcheti
Vamsidhar Velcheti

1 May 2020 in Gastroenterology
Verified
Journal Article
Closed access
ESEli Stahl
Eli Stahl
GRGiulia Roda
Giulia Roda
ADAmanda Dobbyn
Amanda Dobbyn
JHJianzhong Hu
Jianzhong Hu
ZZZhongyang Zhang
Zhongyang Zhang
IPInga Peter
Inga Peter

21 June 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
NBNathaniel Braman
Nathaniel Braman
PPPrateek Prasanna
Prateek Prasanna
KBKaustav Bera
Kaustav Bera
MAMehdi Alilou
Mehdi Alilou
MKMohammadhadi Khorrami
Mohammadhadi Khorrami
Anant MadabhushiAnant Madabhushi
Anant Madabhushi
Purpose: The tumor-associated vasculature (TAV) differs from healthy blood vessels by its convolutedness, leakiness, and chaotic architecture, and these attributes facilitate the creation of a treatment-resistant tumor microenvironment. Measurable differences in these attributes might also help stratify patients by likely benefit of systemic therapy (e.g., chemotherapy). In this work, we present a new category of computational image-based biomarkers called quantitative tumor-associated vasculature (QuanTAV) features, and demonstrate their ability to predict response and survival across multiple cancer types, imaging modalities, and treatment regimens involving chemotherapy. Experimental Design: We isolated tumor vasculature and extracted mathematical measurements of twistedness and organization from routine pretreatment radiology (CT or contrast-enhanced MRI) of a total of 558 patients, who received one of four first-line chemotherapy-based therapeutic intervention strategies for breast (n = 371) or non–small cell lung cancer (NSCLC, n = 187). Results: Across four chemotherapy-based treatment strategies, classifiers of QuanTAV measurements significantly (P < 0.05) predicted response in held out testing cohorts alone (AUC = 0.63–0.71) and increased AUC by 0.06–0.12 when added to models of significant clinical variables alone. Similarly, we derived QuanTAV risk scores that were prognostic of recurrence-free survival in treatment cohorts who received surgery following chemotherapy for breast cancer [P = 0.0022; HR = 1.25; 95% confidence interval (CI), 1.08–1.44; concordance index (C-index) = 0.66] and chemoradiation for NSCLC (P = 0.039; HR = 1.28; 95% CI, 1.01–1.62; C-index = 0.66). From vessel-based risk scores, we further derived categorical QuanTAV high/low risk groups that were independently prognostic among all treatment groups, including patients with NSCLC who received chemotherapy only (P = 0.034; HR = 2.29; 95% CI, 1.07–4.94; C-index = 0.62). QuanTAV response and risk scores were independent of clinicopathologic risk factors and matched or exceeded models of clinical variables including posttreatment response. Conclusions: Across these domains, we observed an association of vascular morphology on CT and MRI—as captured by metrics of vessel curvature, torsion, and organizational heterogeneity—and treatment outcome. Our findings suggest the potential of shape and structure of the TAV in developing prognostic and predictive biomarkers for multiple cancers and different treatment strategies.